🔥 New in @NatureMedicine How do you communicate lifetime benefits expected with HFpEF therapies? New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx #GDMT for HFpEF has finally arrived! 🔗 https://t.co/ozSx3UwkLN

I matched Cardiology at Brigham and Women's Hospital @BrighamFellows Could not have done this without the support of my program leadership @TradIMYale and mentors; eternally grateful 💝💝 A simple kid from Egypt is going from Yale (IM) to Harvard (Cardiology). What a journey!

Sometimes the hardest part isn't the bend, it's the design. Translating a client's sketch into a single, continuous tube of glass with proper electrical paths is like solving a glowing puzzle. This one took three tries to get right.

I am thrilled to have matched at Brigham and Women’s Hospital for my Cardiology Fellowship!! 🫀@BrighamFellows Grateful for my mentors and the opportunities I’ve been given! Incredibly excited for this new chapter!!

EXCITED to match at @BrighamFellows for🫀 fellowship! Grateful to God for mentors who spur me on! @MichaelJBlaha, Jenn Lewey, Esther Choi, Hetty Afari, @albertdansoosei On to the next adventure @BrighamFellows via @UnivofGh->@JohnsHopkinsSPH ->@CiccaroneCenter->@PennIMResidents

Thrilled to welcome our new incoming Cardiology Fellows! 🎓❤️ Can’t wait to see the talent, curiosity, and compassion you’ll bring to the program. Here’s to years of learning, teamwork, and advancing heart care together. #CardioTwitter #MedTwitter

SOTA Review: Nudges in a Learning Health System: Applications to #CKM Care now out in @JACCJournals. Wonderful to work with @Deoliveiragdc @CassSunstein @mvaduganathan @TorBiering & others on a forward-looking vision of coordinated nudges to improve health https://t.co/r6hgKlrORV

Excited to share our paper: “Nudges in a Learning Health System: Applications to Cardiovascular–Kidney–Metabolic Care.” @JACCJournals A deep dive into how behavioral science can enhance CKM care @CassSunstein @ankeetbhatt, @mvaduganathan @hfcollaboratory https://t.co/x5ZZttNYof

Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials In this participant-level pooled analysis of 4 large-scale HFpEF outcome trials, obesity and excess abdominal adiposity were highly

Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART Analysis This participant-level pooled analysis of 3 large-scale outcomes trials supports the use of finerenone in individuals with HFmrEF/HFpEF across a broad range of

Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials: An Initiative From the Heart Failure Collaboratory CKM conditions now have over- lapping disease-modifying, evidence-based treatments, and the therapeutic landscape is expanding with new

Original Article: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias (POTCAST trial) https://t.co/6HUcV2CkKq Editorial: Targeting Potassium for Prevention of Ventricular Arrhythmias https://t.co/IkCIKkxejo #Cardiology

The Heart Failure Collaboratory is deeply saddened to share the passing of our esteemed member, Michael R. Bristow, MD, PhD. We extend our heartfelt condolences to his family, colleagues, and all who were touched by his remarkable life and legacy.

Headline: Albuminuria: The "Silent" Risk We Can’t Afford to Miss in Primary Care I am excited to share our latest article, published today in @bmj_latest , led by @SophieClaudel : "Assessment and management of albuminuria in adults." @bu_bmc_renal @BUMedicine @AHAScience

#GLP-1 receptor agonist exposure with discontinuation before or during early #pregnancy was associated with greater gestational weight gain and increased risk of preterm delivery, gestational #diabetes, and hypertensive disorders. https://t.co/AK53R8UJ1V

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes Among persons with both chronic kidney disease and type 2 diabetes, initial therapy with finerenone plus empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either

788 million people worldwide were living with chronic kidney disease in 2023. Yet neither awareness nor action match the threat posed to health. Our latest Editorial ➡️ "Chronic kidney disease: breaking the silence" https://t.co/cLh5bOHtQp

Proud to close a landmark year for kidney health. With the first @WHO kidney health resolution and a @UN #NCD declaration referencing kidney health, global recognition is growing. Now we must turn commitments into action. Thank you to all who drive this work #KidneyHealthMatters

Time trends in #mortality from heart failure and #atherosclerotic #cardiovascular disease in people with and without #diabetes: a multi-national population-based study https://t.co/5BugVOQAtn #T2D #heartfailure #ASCVD

Finerenone in patients with severe heart failure: The FINEARTS-HF trial Among patients with mildly reduced or preserved LVEF, severe HF was associated with a heightened risk of CV events. Treatment with finerenone appeared safe and effective, regardless of HF severity.

🔥 Big news from CADENCE — positive topline results hitting all the right notes. Targeting PH in heart failure may finally be finding its rhythm. 🫀🎵 @mardigomberg @jeanlucvachiery https://t.co/mDNLNlFl2S

Lots of #CKM discussions @AHAScience. With⏫CKM comorbidity & overlapping treatments, tools should move beyond condition-specific tx optimization. In @JACCJournals from @hfcollaboratory, #ScoreCKM provides a unified medication optimization score across CKM for trials & pt care